Thyroid Cancer Trial, Recruiting NCT05994365 Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT05994365
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part, have signed a consent form, and are able to follow the study requirements
  • You are between 18 and 70 years old, are generally in good physical condition (able to carry out daily activities), and are expected to live for more than 6 months
  • You have been diagnosed through a tissue biopsy with locally advanced or spreading (metastatic) differentiated thyroid cancer, and scans have shown the cancer has grown within the last 18 months
  • Your cancer either does not absorb radioactive iodine well, or you have received a high total dose of radioactive iodine treatment (600 mCi or more), or your cancer continued to grow after radioactive iodine treatment even when it was absorbing the iodine (confirm with trial site for which category applies to you)
  • You have at least one area of cancer that can be measured on a scan
  • Your blood counts and organ function (including blood cells, liver, and kidneys) meet certain minimum health levels based on recent blood tests taken within the past week or two
  • If you can become pregnant, you agree to use contraception during the study and for 6 months after, have a negative pregnancy test before starting, and are not breastfeeding; if you are male, you also agree to use contraception during the study and for 6 months after

Who may not be able to join:

  • You have been diagnosed with another cancer in the past 3 years (some exceptions may apply, such as certain fully cured skin cancers, early-stage cervical changes, or superficial bladder conditions — confirm with trial site)
  • You have had major surgery, an open biopsy, or a serious injury within the past 28 days
  • You have significant heart problems, such as a certain type of irregular heartbeat, reduced heart pumping ability, or a heart attack (confirm with trial site for specific levels)
  • You have a serious active infection that is not under control
  • Your kidneys are failing and you need dialysis
  • You have another serious illness or condition that the doctors feel could make it unsafe for you to take part
  • You have previously been treated with the study drug (anlotinib) or similar targeted cancer drugs such as vandetanib, cabozantinib, lenvatinib, sunitinib, or sorafenib

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: + 86 18622221110

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 August 2023
Est. completion
1 August 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall Response Rate (ORR); Progression-free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov